Axsome Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report covers the 2022 Annual Meeting of Stockholders held on June 3, 2022. The filing details the results of three proposals submitted to security holders regarding director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance.
Material Changes and Voting Results
Of the 38,913,445 shares entitled to vote, 28,369,008 shares (approximately 72.9%) were represented, constituting a quorum. The voting outcomes were as follows:
- Proposal 1 (Election of Class I Director): Roger A. Jeffs, Ph.D., was elected. Votes For: 12,674,227; Votes Withheld: 8,668,220; Broker Non-Votes: 7,026,561.
- Proposal 2 (Ratification of Auditor): Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022. Votes For: 27,697,013; Votes Against: 104,960; Votes Abstaining: 567,035.
- Proposal 3 (Executive Compensation): The compensation of named executive officers was approved on a non-binding advisory basis. Votes For: 20,675,256; Votes Against: 502,810; Votes Abstaining: 164,381; Broker Non-Votes: 7,026,561.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. For further details on the proposals, the filing references the definitive proxy statement on Schedule 14A filed on April 22, 2022.
Investor Verification Checklist
- Verify the total number of shares entitled to vote versus shares represented to confirm quorum status.
- Review the definitive proxy statement (Schedule 14A) for detailed biographies of the elected director and specific compensation metrics.
- Confirm the tenure of the newly elected Class I director, which extends until the 2025 annual meeting.
- Note the significant number of broker non-votes (7,026,561) on the director election and executive compensation proposals.